Novabay Technology Overview We develop

Message Board

Previous

| Next

Post# of 52

Posted On: 02/19/2012 9:46:24 AM

Posted By: crookedneck

Novabay Technology

Overview

We developed our Aganocide compounds through research and development based on the human body’s natural immune system and the molecules involved in combating infections. The body’s primary defense against infection is the anatomic barrier of the skin and mucous membranes. Once pathogens penetrate the primary defense, the next line of defense is provided by the white blood cells. The most numerous of the white blood cells is the neutrophil. When it encounters a bacterium or other pathogen, the neutrophil engulfs it and generates a series of small molecules with which to destroy it. The process in which these molecules are created is called the “oxidative burst”. These molecules typically have a very short life as they are created “on demand” to accomplish a specific task. We have focused our efforts on understanding these molecules and finding ways, primarily by chemical modification, to impart qualities to them to allow them to be developed as therapeutic products.

Aganocide Compounds

Our proprietary Aganocide compounds work by mimicking our own natural defense against infection. Since our immune system works without ever creating resistance, NovaBay has taken the effective and rapidly acting molecules that function within our own bodies and created stable analogs of these molecules. Our lead Aganocide compound is NVC-422, but we have synthesized several other analogs.

Our Aganocide compounds are:

Fast acting

Broad in spectrum of activity

Effective against multi-drug resistant bacteria

Effective against biofilm

Have a good safety profile

Fast

Unlike most antibiotics, which can take many hours to kill certain kinds of bacteria, NVC-101 and the Aganocide compounds, even at small doses, can kill bacteria in minutes.

Broad spectrum of activity

NVC-101 and our Aganocide compounds have killed, in vitro , all bacteria, viruses, yeasts and fungi against which they have been tested.

Effective against multi-drug resistant bacteria

Our Aganocide compounds were highly effective in in vitro studies against multi-drug resistant bacteria including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE).

Effective against biofilm

In data developed at an independent laboratory on our behalf and at our direction, NVC-422 was demonstrated to be highly effective against well-established biofilm grown on urinary tract catheters.

High therapeutic index

Both NVC-101 and NVC-422 demonstrate greater in vitro therapeutic index (ratio of toxicity to efficacy) than existing topical antiseptics.

Biofilm

The Center for Integrative Biology and Infectious Diseases of the National Institutes of Health estimates that 80% of all infections in the US involve biofilm. At present, there is no effective treatment that both disrupts the development of biofilm and eradicates the bacteria within. NovaBay’s products, however, have demonstrated in in-vitro and in-vivo studies the ability to penetrate biofilm, as well as to kill microbes sheltered within the biofilm.

Biofilm is often associated with conditions such as:

Sinus infections

Ear infections

Chronic wounds

Infections related to cystic fibrosis

Biofilms can also be found on the surface of medical devices such as:

Catheters

Stents

Contact lenses

Bone implants

Cochlear implants

Breast implants

Many bacteria spend much of their existence within a matrix that they create, called biofilm. Biofilm consists of mucopolysaccharide (or slime-like) structures produced by microorganisms as a defense mechanism against their environment. Encased in biofilm, bacteria can survive for prolonged periods by assuming a dormant state. When bacteria are in a dormant state, they are largely immune to antibiotics, which are generally only effective against bacteria during specific non-dormant stages in their life cycle. When bacteria are protected by biofilm, antibiotics frequently provide only temporary relief and bacteria can eventually emerge from their biofilm to re-infect the patient. In biofilm, bacteria are also largely protected from white blood cells that normally kill most pathogens that enter the body. White blood cells combat bacteria by engulfing them, which they are unable to do once bacteria have created biofilm. Furthermore, many commonly used antiseptics are neutralized by biofilm.

Antibiotic Resistance

Bacteria are becoming resistant to different classes of existing antibiotics at increasing rates. These increasing levels of resistance are principally the result of repeated exposure of bacteria to non-lethal quantities of antibiotics and the ability of certain bacteria to transmit mutant genes to other bacterial species, thus enabling different species of bacteria to survive the antibiotic to which the first species was exposed. The increase in antibiotic resistance since 1990 has been substantial and is especially prevalent in hospital environments. According to the State of Pennsylvania 2005 Report, 14% of hospital ICU infections were fatal and those infections accounted for $2.9 billion in increased costs.

NovaBay Publications

Published Articles

2011

Structure stability/activity relationships of sulfone stabilized
N,N- dichloroamines

Novel 3-chlorooxazolidin-2-ones as antimicrobial agents

Novel N- chloroheterocyclic antimicrobials

Chemical Characterization and Biological Properties of NVC-422,
a Novel, Stable N- Chlorotaurine Analog

2009

N,N- Dichloroaminosulfonic acids as novel topical antimicrobial agents

Stieglitz rearrangement of N,N- dichloro-β,β-disubstituted taurines under mild aqueous conditions

Quaternary ammonium N , N -dichloroamines as topical, antimicrobial agents

2008